drugset / Trial / NCT07406932
A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective investigation comparing the efficacy and safety of Janus kinase inhibitors versus calcineurin inhibitors as initial therapy for interstitial lung disease associated with antisynthetase syndrome. The goal is to determine which treatment is more effective at improving lung function and preventing disease progression, while comparing their safety profiles. The findings will help provide clearer treatment guidance for doctors and patients.
Timeline
- Start
- 2026-05-18
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 4 mg | Oral |
| Subject | Cyclosporine | Peptide | 2 mg/kg | Oral |
| Subject | Cyclosporine | Peptide | 5 mg/kg | Oral |
| Subject | Tacrolimus | Small molecule | 0.075 mg/kg | Oral |
| Subject | Tofacitinib | Small molecule | 5 mg | Oral |
| Subject | Upadacitinib | Small molecule | 15 mg | Oral |